FULC
Fulcrum Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-24
Figures on this page computed 2026-11-08 12:40 UTC
Last close
3.77USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-24
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-065197
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-24
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-065197
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-07-30
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-07-30
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-065197
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-065197
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-065197
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-07-30
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Growth is the furthest below its sector's middle: 0.02 against 0.50 on the market's range.
- Growth-100.0%2 of 100, below its sector
- Returns on capital-21.5%26 of 100, above its sector
- Marginsn/anot placed
- Price0.8x76 of 100, above its sector
- Safety27.4094 of 100, above its sector
- What it pays outn/anot placed
- Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
What it sells, to whom
lens 8 of 9The filer tagged nothing for this, so there is nothing filed to draw.
Nothing is drawn in its place. The other lenses are unaffected.
No concentration of risk disclosure was tagged in this filing and no concentration note was tagged either. That is not a statement that the company has no concentration.